Baker Bros. Advisors’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-9,244,665
| Closed | -$627M | – | 116 |
|
|
2019
Q3 | $627M | Sell |
9,244,665
-16,257
| -0.2% | -$1.12M | 4.27% | 7 |
|
|
2019
Q2 | $539M | Sell |
9,260,922
-938,021
| -9% | -$55.6M | 3.66% | 8 |
|
|
2019
Q1 | $714M | Sell |
10,198,943
-1,545,067
| -13% | -$115M | 4.57% | 7 |
|
|
2018
Q4 | $756M | Sell |
11,744,010
-2,046,960
| -15% | -$143M | 6.19% | 5 |
|
|
2018
Q3 | $968M | Buy |
13,790,970
+396
| +0% | +$23.2K | 6.38% | 5 |
|
|
2018
Q2 | $695M | Buy |
13,790,574
+638
| +0% | +$25.3K | 5.22% | 6 |
|
|
2018
Q1 | $431M | Buy |
13,789,936
+8,834
| +0.1% | +$293K | 3.66% | 7 |
|
|
2017
Q4 | $471M | Buy |
13,781,102
+622
| +0% | +$19.8K | 4.09% | 6 |
|
|
2017
Q3 | $442M | Buy |
13,780,480
+614
| +0% | +$19.4K | 3.59% | 6 |
|
|
2017
Q2 | $449M | Buy |
13,779,866
+8,884
| +0.1% | +$281K | 3.92% | 6 |
|
|
2017
Q1 | $434M | Buy |
13,770,982
+680
| +0% | +$20.1K | 3.55% | 5 |
|
|
2016
Q4 | $405M | Hold |
13,770,302
| – | – | 3.97% | 7 |
|
|
2016
Q3 | $398M | Buy |
13,770,302
+101,436
| +0.7% | +$2.83M | 3.61% | 9 |
|
|
2016
Q2 | $354M | Buy |
13,668,866
+9,034
| +0.1% | +$240K | 3.71% | 9 |
|
|
2016
Q1 | $338M | Buy |
13,659,832
+568
| +0% | +$15.6K | 3.57% | 9 |
|
|
2015
Q4 | $481M | Buy |
13,659,264
+936
| +0% | +$25.1K | 3.98% | 8 |
|
|
2015
Q3 | $289M | Buy |
13,658,328
+730
| +0% | +$18.8K | 2.67% | 10 |
|
|
2015
Q2 | $380M | Buy |
13,657,598
+656
| +0% | +$18.5K | 3.33% | 10 |
|
|
2015
Q1 | $417M | Buy |
13,656,942
+624
| +0% | +$19.8K | 3.47% | 11 |
|
|
2014
Q4 | $437M | Buy |
13,656,318
+700
| +0% | +$22.8K | 4.46% | 8 |
|
|
2014
Q3 | $387M | Buy |
13,655,618
+716
| +0% | +$20K | 4.87% | 7 |
|
|
2014
Q2 | $374M | Buy |
13,654,902
+752
| +0% | +$20K | 4.58% | 7 |
|
|
2014
Q1 | $360M | Buy |
13,654,150
+3,315
| +0% | +$95.1K | 4.57% | 7 |
|
|
2013
Q4 | $400M | Hold |
13,650,835
| – | – | 5.63% | 7 |
|
|
2013
Q3 | $417M | Hold |
13,650,835
| – | – | 5.93% | 7 |
|
|
2013
Q2 | $433M | Buy |
+13,650,835
| New | +$448M | 8.56% | 3 |
|
Baker Bros. Advisors's GHDX Position: Q4 2019 in Review
Baker Bros. Advisors sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 9,244,665 shares — an estimated $627M sold.
Baker Bros. Advisors first reported a position in GHDX in Q2 2013 and held it in 26 quarters. The position peaked at $968M in Q3 2018. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Baker Bros. Advisors reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Baker Bros. Advisors sold 9,244,665 Genomic Health, Inc. shares in Q4 2019, an estimated $627M.
- Baker Bros. Advisors first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 26 quarters.
- Baker Bros. Advisors's Genomic Health, Inc. position peaked at $968M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.